Evaluation of the steroid sparing effects of Mepolizumab using the Glucocorticoid Toxicity Index

Research output: Contribution to conferencePoster

Abstract

Background: The Glucocorticoid Toxicity Index(GTI) systematically captures steroid toxicity and measures change in glucocorticoid(GC) associated morbidity using two scores. The Cumulative Worsening Score(CWS) is an additive record of all GC-toxicities encountered by a patient therefore the score is always >0, unless no toxicity has occurred. The Aggregate Improvement Score(AIS) counts present toxicity allowing both improvement and worsening; a negative score reflects reduced toxicity.

Objective: Use the GTI to assess GC-associated morbidity in a severe asthma cohort commencing Mepolizumab(MEPO) in routine clinical care.

Methods: Patients with GC-dependent asthma underwent GTI assessment on commencing MEPO(V1) and after 12 months on MEPO(V2). The validated GTI includes focused medical history, examination, medication review, observations, HbA1c and LDL.

Results: 22 patients(15F:7M), mean age 52.4 y(range 30.5-68.3). Cumulative prednisolone (PRED) in 12 months preceding V1 was 7446mg(range 1400-22,460), mean daily PRED 20.4mg. Cumulative PRED in V1-V2 was 4754mg (range: 0-16,940), mean 12.9mg/day.

14 (64%) had a CWS of 0 indicative of no new GC-toxicity between V1-2; 8(36%) patients had a CWS of >0 (median 30, range 19-93) indicating increased toxicity in at least 1 domain. 19(86%) had a negative AIS, indicating overall improvement in GC-toxicity (mean AIS -56.5).

A rising CWS was associated with age [OR= 1.27 (1.01-1.60)] and higher mean daily PRED dose [OR=1.19 (0.92-1.53)].

Conclusion: MEPO reduces PRED requirements with associated reduction in GC-toxicity over a 1-year period as measured by the GTI. Age and mean daily dose are risk factors for worsening GC toxicity despite dose reduction.

Original languageEnglish
Publication statusPublished - 2019
EventEuropean Respiratory Society International Congress 2019 - Spain, Madrid, Spain
Duration: 28 Sept 201902 Oct 2019
https://www.ers-education.org/events/international-congress/madrid-2019/

Conference

ConferenceEuropean Respiratory Society International Congress 2019
Abbreviated titleERS 2019
Country/TerritorySpain
CityMadrid
Period28/09/201902/10/2019
Internet address

Fingerprint

Dive into the research topics of 'Evaluation of the steroid sparing effects of Mepolizumab using the Glucocorticoid Toxicity Index'. Together they form a unique fingerprint.

Cite this